Literature DB >> 28939155

French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version.

V Cottin1, B Crestani2, J Cadranel3, J-F Cordier4, S Marchand-Adam5, G Prévot6, B Wallaert7, E Bergot8, P Camus9, J-C Dalphin10, C Dromer11, E Gomez12, D Israel-Biet13, S Jouneau14, R Kessler15, C-H Marquette16, M Reynaud-Gaubert17, B Aguilaniu18, D Bonnet19, P Carré20, C Danel21, J-B Faivre22, G Ferretti23, N Just24, F Lebargy25, B Philippe26, P Terrioux27, F Thivolet-Béjui28, B Trumbic29, D Valeyre30.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28939155     DOI： 10.1016/j.rmr.2017.07.017

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN： 0761-8425            Impact factor:   0.622


× No keyword cloud information.
  13 in total

1.  Familial pulmonary fibrosis: a world without frontiers.

Authors:  Raphael Borie; Bruno Crestani
Journal:  J Bras Pneumol       Date:  2019-10-07       Impact factor: 2.624

2.  Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases.

Authors:  Mouhamad Nasser; Marion Colevray; Salim A Si-Mohamed; Olivier Nempont; Pierre-Jean Lartaud; Anna Vlachomitrou; Thomas Broussaud; Kais Ahmad; Julie Traclet; Vincent Cottin; Loic Boussel
Journal:  Eur Radiol       Date:  2022-01-14       Impact factor: 7.034

Review 3.  Interstitial Pneumonia With Autoimmune Features (IPAF).

Authors:  Ligia Fernandes; Mouhamad Nasser; Kais Ahmad; Vincent Cottin
Journal:  Front Med (Lausanne)       Date:  2019-09-27

4.  [Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020].

Authors:  C Andrejak; V Cottin; B Crestani; D Debieuvre; J Gonzalez-Bermejo; C Morelot-Panzini; B Stach; Y Uzunhan; B Maitre; C Raherison
Journal:  Rev Mal Respir       Date:  2020-11-27       Impact factor: 0.622

5.  Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.

Authors:  Manon Belhassen; Faustine Dalon; Maëva Nolin; Eric Van Ganse
Journal:  Respir Res       Date:  2021-05-04

6.  Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China.

Authors:  Xie Xiaohong; Wang Liqiang; Li Na; Lin Xinqing; Qin Yinyin; Liu Ming; Ouyang Ming; Han Qian; Luo Qun; Li Shiyue; Li Chunyan; Wang Xiaoqian; Yang Shuanying; Huang Wei; Liu Mei; Wang Ping; Zhou Chengzhi
Journal:  Front Mol Biosci       Date:  2021-03-31

7.  Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis.

Authors:  Xuanlin Li; Xueqing Yu; Yang Xie; Zhenzhen Feng; Yanfang Ma; Yaolong Chen; Jiansheng Li
Journal:  Ann Transl Med       Date:  2020-11

8.  One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.

Authors:  George A Diaz; Simon A Jones; Maurizio Scarpa; Karl Eugen Mengel; Roberto Giugliani; Nathalie Guffon; Isabela Batsu; Patricia A Fraser; Jing Li; Qi Zhang; Catherine Ortemann-Renon
Journal:  Genet Med       Date:  2021-04-19       Impact factor: 8.864

9.  Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2017-11-14

Review 10.  Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Authors:  Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter
Journal:  Respir Res       Date:  2020-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.